129 related articles for article (PubMed ID: 26199090)
1. Psoriasis in elderly and non-elderly population: clinical and molecular features.
Napolitano M; Balato N; Ayala F; Patruno C; Patrì A; Megna M; Balato A
G Ital Dermatol Venereol; 2016 Dec; 151(6):587-595. PubMed ID: 26199090
[TBL] [Abstract][Full Text] [Related]
2. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
3. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
5. Safety concerns with current treatments for psoriasis in the elderly.
Di Caprio R; Caiazzo G; Cacciapuoti S; Fabbrocini G; Scala E; Balato A
Expert Opin Drug Saf; 2020 Apr; 19(4):523-531. PubMed ID: 32056449
[No Abstract] [Full Text] [Related]
6. Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.
Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Sonntag D; Goerdt S; Peitsch WK
PLoS One; 2015; 10(12):e0144335. PubMed ID: 26633680
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.
Semble AL; Davis SA; Feldman SR
Am J Clin Dermatol; 2014 Feb; 15(1):37-43. PubMed ID: 24281790
[TBL] [Abstract][Full Text] [Related]
8. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
9. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
10. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.
Balato A; Schiattarella M; Di Caprio R; Lembo S; Mattii M; Balato N; Ayala F
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1016-24. PubMed ID: 24033358
[TBL] [Abstract][Full Text] [Related]
11. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic.
Bonifati C; Graceffa D; Lora V; Maiani E
G Ital Dermatol Venereol; 2016 Dec; 151(6):596-602. PubMed ID: 26505567
[TBL] [Abstract][Full Text] [Related]
13. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics.
Geale K; Henriksson M; Schmitt-Egenolf M
Br J Dermatol; 2016 Mar; 174(3):579-87. PubMed ID: 26616003
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
15. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
Lecha M; Mirada A; López S; Artés M;
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
[TBL] [Abstract][Full Text] [Related]
16. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
17. Pediatric psoriasis: updates in biologic therapies.
Sukhatme SV; Gottlieb AB
Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
